Showing results (1591-1600 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 1, 1994
Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixolD Fan, G Poste, C Seid, et al.
Investigational New Drugs|January 1, 1994
Phase II trial of fotemustine in patients with metastatic malignant melanomaC I Falkson, G Falkson, H C Falkson
Investigational New Drugs|January 1, 1994
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trialM R Mullane, R L Schilsky, R B Carroll, et al.
Investigational New Drugs|December 6, 2023
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-IDaiki Tsuji, Shigeru Nakagaki, Itsuki Yonezawa, et al.
Investigational New Drugs|January 10, 2024
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector functionJingying Yue, Shuai Shao, Jie Zhou, et al.
Investigational New Drugs|December 21, 2023
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cellsMahtab Afsharzadeh, Jaleh Varshosaz, Mina Mirian, et al.
Investigational New Drugs|July 22, 2024
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion studyDongmei Ji, Weina Shen, Ting Li, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
Investigational New Drugs|June 5, 2024
177Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic modelSujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
Investigational New Drugs|July 11, 2024
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancerJing Zhang, Wenwei Yang, Junbao Liu, et al.
Pageof 372